Marie Gérardin

731 total citations
40 papers, 438 citations indexed

About

Marie Gérardin is a scholar working on Toxicology, Pharmacology and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Marie Gérardin has authored 40 papers receiving a total of 438 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Toxicology, 10 papers in Pharmacology and 7 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Marie Gérardin's work include Pharmaceutical Practices and Patient Outcomes (7 papers), Opioid Use Disorder Treatment (6 papers) and Forensic Toxicology and Drug Analysis (6 papers). Marie Gérardin is often cited by papers focused on Pharmaceutical Practices and Patient Outcomes (7 papers), Opioid Use Disorder Treatment (6 papers) and Forensic Toxicology and Drug Analysis (6 papers). Marie Gérardin collaborates with scholars based in France and United States. Marie Gérardin's co-authors include Caroline Victorri‐Vigneau, Pascale Jolliet, Marie Grall‐Bronnec, Marylène Guerlais, Morgane Rousselet, Françoise Haramburu, Yannick Arimone, Hélène Théophile, Dominique Hillaire‐Buys and Marie‐Blanche Valnet‐Rabier and has published in prestigious journals such as PLoS ONE, Drug and Alcohol Dependence and British Journal of Clinical Pharmacology.

In The Last Decade

Marie Gérardin

36 papers receiving 424 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Marie Gérardin France 13 126 123 71 69 68 40 438
Michel Mallaret France 13 152 1.2× 103 0.8× 52 0.7× 26 0.4× 56 0.8× 47 497
Anne Bénard‐Laribière France 14 94 0.7× 58 0.5× 105 1.5× 23 0.3× 75 1.1× 27 515
Sylvie Deheul France 15 119 0.9× 73 0.6× 84 1.2× 79 1.1× 14 0.2× 54 506
Bernard Delorme France 9 81 0.6× 42 0.3× 42 0.6× 14 0.2× 112 1.6× 10 396
S. Welch Canada 8 65 0.5× 72 0.6× 86 1.2× 100 1.4× 30 0.4× 10 724
Pascal Caillet France 13 28 0.2× 67 0.5× 63 0.9× 42 0.6× 22 0.3× 40 467
Laure Pourcel France 10 63 0.5× 46 0.4× 18 0.3× 23 0.3× 19 0.3× 15 330
Andrew D. Mosholder United States 15 40 0.3× 69 0.6× 192 2.7× 136 2.0× 18 0.3× 38 743
Amélie Daveluy France 14 267 2.1× 132 1.1× 49 0.7× 69 1.0× 8 0.1× 78 602
Basil G. Bereza Canada 15 16 0.1× 156 1.3× 83 1.2× 73 1.1× 69 1.0× 22 556

Countries citing papers authored by Marie Gérardin

Since Specialization
Citations

This map shows the geographic impact of Marie Gérardin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marie Gérardin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marie Gérardin more than expected).

Fields of papers citing papers by Marie Gérardin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marie Gérardin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marie Gérardin. The network helps show where Marie Gérardin may publish in the future.

Co-authorship network of co-authors of Marie Gérardin

This figure shows the co-authorship network connecting the top 25 collaborators of Marie Gérardin. A scholar is included among the top collaborators of Marie Gérardin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marie Gérardin. Marie Gérardin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Rousselet, Morgane, et al.. (2024). “Naloxone? Not for me!” First cross-assessment by patients and healthcare professionals of the risk of opioid overdose. Harm Reduction Journal. 21(1). 20–20. 1 indexed citations
2.
Guerlais, Marylène, et al.. (2023). Nitrous oxide: a unique official French addictovigilance national survey. Frontiers in Public Health. 11. 1167746–1167746. 12 indexed citations
3.
Guerlais, Marylène, et al.. (2023). Nitrous oxide in France: Evolution of complications reported to the French monitoring system in the context of information from health authorities and regulatory measures. International Journal of Drug Policy. 144. 104172–104172. 2 indexed citations
4.
Gérardin, Marie, Morgane Rousselet, A. Masseau, et al.. (2021). Descriptive analysis of sickle cell patients living in France: The PHEDRE cross-sectional study. PLoS ONE. 16(3). e0248649–e0248649. 3 indexed citations
5.
Caillet, Pascal, Morgane Rousselet, Marie Gérardin, Pascale Jolliet, & Caroline Victorri‐Vigneau. (2020). Prevalence of zolpidem use in France halved after secure prescription pads implementation in 2017: A SNDS database nested cohort study. PLoS ONE. 15(2). e0228495–e0228495. 11 indexed citations
6.
Gérardin, Marie, Morgane Rousselet, Pascal Caillet, et al.. (2019). French national health insurance database analysis and field study focusing on the impact of secure prescription pads on zolpidem consumption and sedative drug misuse: ZORRO study protocol. BMJ Open. 9(6). e027443–e027443. 14 indexed citations
7.
Bulteau, Samuel, Marie Grall‐Bronnec, Marie Gérardin, et al.. (2017). Psychiatric disorders, acne and systemic retinoids: comparison of risks. Expert Opinion on Drug Safety. 16(9). 989–995. 10 indexed citations
8.
Rousselet, Morgane, Fanny Feuillet, Marie Gérardin, et al.. (2017). The French addictovigilance network clinical assessment: Z-drugs, true false twins. Expert Opinion on Drug Safety. 16(9). 1063–1069. 15 indexed citations
9.
10.
Victorri‐Vigneau, Caroline, Jean-Benoît Hardouin, Morgane Rousselet, et al.. (2016). Multicentre study for validation of the French addictovigilance network reports assessment tool. British Journal of Clinical Pharmacology. 82(4). 1030–1039. 2 indexed citations
11.
12.
Théophile, Hélène, Jean-Paul Dutertre, Marie Gérardin, et al.. (2015). Validation and Reproducibility of the Updated French Causality Assessment Method: an Evaluation by Pharmacovigilance Centres & Pharmaceutical Companies. Therapies. 70(5). 465–476. 20 indexed citations
13.
Daveluy, Amélie, Hélène Geniaux, Céline Eiden, et al.. (2015). Illicit drugs or medicines taken by parachuting. Fundamental and Clinical Pharmacology. 30(2). 185–190. 13 indexed citations
14.
Victorri‐Vigneau, Caroline, Marie Gérardin, Morgane Rousselet, et al.. (2014). An Update on Zolpidem Abuse and Dependence. Journal of Addictive Diseases. 33(1). 15–23. 49 indexed citations
15.
Clément, Renaud, et al.. (2013). Medical, social, and law characteristics of intoxicant's users medically examined in police custody. Journal of Forensic and Legal Medicine. 20(8). 1083–1086. 8 indexed citations
16.
Arimone, Yannick, Jean-Paul Dutertre, Marie Gérardin, et al.. (2013). Updating the French Method for the Causality Assessment of Adverse Drug Reactions. Therapies. 68(2). 69–76. 58 indexed citations
17.
Victorri‐Vigneau, Caroline, et al.. (2012). Diagnostic de pharmacodépendance : comparaison des points de vue du patient et du médecin. Therapies. 67(2). 167–172. 2 indexed citations
18.
Gérardin, Marie, et al.. (2011). Management of cannabis use during pregnancy: an assessment of healthcare professionals' practices. Pharmacoepidemiology and Drug Safety. 20(5). 464–473. 12 indexed citations
19.
Debruyne, Danièle, Reynald Le Boisselier, Samira Djezzar, et al.. (2010). La méphédrone : une designer drug d’usage récent en France. Therapies. 65(6). 519–524. 15 indexed citations
20.
Lagausie, Pascal de, Marie Gérardin, Muriel Le Bourgeois, et al.. (1998). Invaginations intestinales itératives et mucocèle appendiculaire chez un enfant atteint de mucoviscidose. Archives de Pédiatrie. 5(4). 400–403. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Michel Mallaret Breakdown of academic impact, for papers by Anne Bénard‐Laribière Breakdown of academic impact, for papers by Sylvie Deheul Breakdown of academic impact, for papers by Bernard Delorme Breakdown of academic impact, for papers by S. Welch Breakdown of academic impact, for papers by Pascal Caillet Breakdown of academic impact, for papers by Laure Pourcel Breakdown of academic impact, for papers by Andrew D. Mosholder Breakdown of academic impact, for papers by Amélie Daveluy Breakdown of academic impact, for papers by Basil G. Bereza
Rankless by CCL
2026